Komentář k článku Biosimilární infliximab v terapii anti-TNF naivních pacientů s IBD – jednoleté klinické sledování
Peter D. R. Higgins1
+ Pracoviště
Celý článek je dostupný po přepnutí na anglickou verzi webové stránky (v pravém horním rohu).
Literatura
1. Kolar M, Duricova D, Bortlik M et al. Biosimilar infliximab in anti-TNF-naïve IBD patients – 1-year clinical follow-up. Gastroent Hepatol 2016; 70 (6): 514–522. doi: 10.14735/amgh2016514.
2. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 (5517): 495–497.
3. Biocompare. [online]. Available from: www.biocompare.com.
4. Cauchi R. State laws and legislation related to biologic medications and substitution of biosimilars. [online]. Available from: www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx.
5. Gibson DJ, Heetun ZS, Redmond CE et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13 (2): 330–335. doi: 10.1016/j.cgh.2014. 07.041.
6. Colombel JF, Reinisch W, Mantzaris GJ et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease – a SONIC post hoc analysis. Aliment Pharmacol Ther 2015; 41 (8): 734–746. doi: 10.1111/apt.13139.
7. Bouguen G, Levesque BG, Pola S et al. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2014; 20 (2): 231–239. doi: 10.1097/01.MIB.0000437985.00190.aa.
8. Reinink AR, Lee TC, Higgins PD. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis 2016; 22 (8): 1859–1869. doi: 10.1097/ MIB.0000000000000816.
9. Gisbert JP, Bermejo F, Pérez-Calle JL et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15 (8): 1190–1198. doi: 10.1002/ibd.20933.